Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738818 | 1.00 | PRMT5 (0.40) | PRMT5WDR77ADKENPP1DGAT1 | |
| SCHEMBL13243594 | 0.85 | DGAT1 (0.38) | PRMT5WDR77DGAT1 | |
| SCHEMBL18547536 | 0.84 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL98891 | 0.84 | FGFR1 (0.35) | DGAT1 | |
| SCHEMBL127257 | 0.84 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL6672255 | 0.83 | USP2 (0.40) | PRMT5WDR77ADKENPP1 | |
| SCHEMBL13737015 | 0.83 | XDH (0.39) | PRMT5WDR77DGAT1 | |
| SCHEMBL20893945 | 0.83 | ALDH1A1 (0.36) | PRMT5WDR77DGAT1 | |
| SCHEMBL17858713 | 0.82 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL29416267 | 0.82 | DGAT1 (0.30) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117425660-A | Aromatic heterocyclic compound, intermediate thereof, pharmaceutical composition and application | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-114126620-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2022-03-01 | — | — | CN | disclosed |